lopinavirritonavir lpvr sold brand name kaletra among others fixeddose combination antiretroviral medication treatment prevention combines lopinavir low dose generally recommended use may used prevention needlestick injury potential taken mouth tablet capsule common side effects include diarrhea vomiting feeling tired headaches muscle severe side effects may include pancreatitis liver problems high blood commonly used pregnancy appears medications hiv protease ritonavir functions slowing breakdown lopinavirritonavir single medication approved use united states world health organizations list essential lopinavirritonavir preferred combination hiv firstline therapy united due higher pill burden compared protease inhibitorbased regimens increased gastrointestinal intolerance longer recommended treatmentnaive common adverse effects observed lopinavirritonavir diarrhea nausea key clinical trials moderate severe diarrhea occurred patients moderatesevere nausea common adverse effects include abdominal pain asthenia headache vomiting particularly children raised liver enzymes hyperlipidemia hypertriglyceridemia hypercholesterolemia also commonly observed lopinavirritonavir treatmentcitation needed lopinavirritonavir anticipated varying degrees interaction medications also andor pgp people structural heart disease preexisting conduction system abnormalities ischaemic heart disease cardiomyopathies use lopinavirritonavir march us food drug administration notified healthcare professionals serious health problems reported premature babies receiving lopinavirritonavir oral solution probably propylene glycol content recommend use avoided premature abbott laboratories via spinoff abbvie one earliest users advanced photon source aps national synchrotronradiation light source argonne national laboratory one early research projects undertaken aps focused proteins human immunodeficiency virus hiv using aps beam line xray crystallography researchers determined viral protein structures allowed determine approach development hiv protease inhibitors key enzyme target processes hiv polyproteins infection function allows lifecycle virus proceed result structurebased drug design approach using argonne aps abbott able develop new products inhibit protease therefore stop virus lopinavir developed abbott attempt improve upon companys earlier protease inhibitor ritonavir specifically regard serum proteinbinding properties reducing interference serum protease enzyme inhibition hiv resistance profile reducing ability virus evolve resistance administered alone lopinavir insufficient bioavailability however like several hiv protease inhibitors blood levels greatly increased low doses ritonavir potent inhibitor intestinal hepatic cytochrome would otherwise reduce drug levels abbott therefore pursued strategy coadministering lopinavir doses ritonavir subtherapeutic respect hiv inhibition hence lopinavir formulated marketed fixeddose combination medication ritonavircitation needed lopinavirritonavir approved us food drug administration fda september europe march patent scheduled expire us june neededneeds update march pandemic israeli government announced would force abbvie license patents lopinavirritonavir response abbvie announced would cease enforcing patents drug result high prices spread hiv infection government thailand issued compulsory license january produce andor import generic versions lopinavir response abbott laboratories withdrew registration lopinavir seven new drugs thailand citing thai governments lack respect abbotts attitude denounced several ngos worldwide including netstrike initiated act upparis public call boycott abbotts medicines french ngo heatstable pellets taken mouth developed data looked promising benefit unclear march nonblinded randomized trial found lopinavirritonavir useful treat severe trial medication started typically around days start httpsenwikipediaorgwikilopinavirritonavir